, involving nearly 75 000 women, showed a highly signifint reduction in the annual death rate from the disease. This information, because of the numbers of women involved, is reliable and did persuade most surgeons and, if translated into routine clnical practic worldwide, would save many thousands of lives each year. Phase I and II studie of new treatments, however, because they are carried out on very small numbers of carefully selected patients, sometimes suggest that the new drug or schedule can confer dramatic improvements wch subsequently turn out not to be real (Tannock, 1992) . The only reliable way to detect small but important differences (Antman et al., 1985) , or to confirm whether new treatments really are effective, is to test the new treatments against standard therapy in randomised clinical trials.
In recent years it has become clear that such studies must be large in order to detect the small or moderate differences between treatments that can rlsticaly be expeted. Furthermore, the accrual rate must not be so slow that the results are overtaken by changing conditions or practice. Currently, the number of patients with cancer who enter clinical trials represents only a tiny percentage of the available patient pool (Friedman and Cain, 1990) Previous research (Mackillop et al., 1989) has indicated that among lay individuals (never having had cancer) approximately one-half think that they would agree to participate in research protocols. One of the most commonly stated reasons is that participation would help others in the same situation in the future. However, this study was in a population that was highly selective. The purpose of the present survey was to explore patients' views about clinical trials, with the aim of devising a strategy to encourage patients to consider entering them. With this in mind, the questionnaire attempted to determine which aspects of clinical trials appeal to patients and which are a deterrent, and whether their views on these issues influence their willingness to participate. This report presents the findings from the study, which was carried out in seven oncology centres in the UK, as the first step in devising information that could be provided to patients about trials in a neutral but informative manner (Angell, 1984) .
Methods

Format
The pilot and study questionnaires were designed by members of a small Working Group of the UKCCCR, convened specifically to consider how to mobilise patients to seek opportunities to participate in research studies.
A pilot questionnaire contained open-ended questions, which it was hoped would provide indicators of the key issues for patients in relation to participation in research trials, which could then be developed as precoded items on the subsequent questionnaire. The pilot questionnaire was tested on 34 out-patients attending oncology clinics in the UK; it was introduced and explained to the patient by the clinic nurse. The only criteria for entry were that the patient had been informed of his (or her) diagnosis, in order to avoid distress in completing a questionnaire clearly related to cancer, and could adequately understand English.
The study questionnaire was drawn up in the light of the results from the pilot phase, and tested with the clinic nurses to ensure that it was easily understood and contained pertinent items. It was based on a closed, multiple-choice format, taking care to avoid leading questions, and was designed for self-completion by patients. Table I ) and -regardless of whether they were appealing or notwhich three of the items listed were considered the most important. Finally, patients were asked to indicate whether they would participate in a research trial, given the opportunity; if they were not willing, they were asked to explain their reasons. (Table H) .
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Respondents were asked if they thought they would agree to take part in a research trial for their illness. It was explained that 'this would mean that you would be allocated to either the new treatment or to standard treatments'. Fortytwo per cent said they would agree to take part and 10% said they would not (or did not answer the question); 48% were uncertain. Those who replied that they would not agree to take part or were uncertain were asked for their reasons. The respondents were most likely to select as their reason 'would prefer doctor to make the decision about the treatment' (51%) and 'would worry about receiving new treatment' (33%); 9% selected 'would prefer to be able to choose treatment' and 7% gave a variety of other free response reasons.
Tale II Aspects of research trials ranked as the three most important (1-3 in order ofimportance) by the 68 patients (91 %) who indicated on the questions their first choice; 66 patients (88%) possibly not be as good as, standard treatments. However, they also need to be reassured that by the time new treatments are studied in randomised national trials, much information about them has already been gained in phase I and II trials. This should help to remove the fear of the unknown. It would also counter the concerns expressed in this survey that clinical trials may lead to a feeling of being experimented on, and that they give neither the doctor nor the patient any choice in the management of the disease.
The patients in this survey placed great emphasis on the importance of being treated by a doctor who specialised in their cancer, and they clearly found this to be reassuring. However, many patients in the UK never see a cancer specialist at any time in their treatment and this might be a factor adding to the anxiety associated with a diagnosis of cancer. This may alter if the recently proposed changes in cancer senrices are implemented. Also important to patients is the closer monitoring that is often associated with trials; this view might have an impact on patients' willingness to participate in the increasingly common pragmatic trials which manage to accrue the numbers of patients needed because they do not demand extra tests and detailed data collection. The majority of patients found the concept of new treatments to be appealing, but were against being given treatments described as experinental, presumably reflecting how the treatment being tested is described, and emphasising how dependent informed consent can be on the way information is presented to the patient. More care in explaining how much is known about the new treatment should help reduce the fear of experimental therapy. Clinical researchers need to review the way in which clinical trials are described to potential participants, and it may be timely to undertake research into alternative ways of inviting patients with cancer to volunteer for research protocols. It is encouraging that the Department of Health has identified as one of the priorities for research in cancer the issue of increasing recruitment into trials.
There is accumulating evidence suggesting that patients in clinical trials do better than those treated in an ad hoc manner. In a study of participants in trials for non-small-cell lung cancer (Davis et al., 1985) , which attempted to exclude most factors which might have influenced survival when comparing a trial control group with a non-trial control group, the authors postulated that there were at least four reasons why trial patients did better. These were differences in (1) preoperative evaluation, staging and subsequent follow-up; (2) surgical technique; (3) placebo effects; and (4) patients' motivation. It is unlikely that the differences will be entirely artefactual arising from, for example, differences in patient selection, or a guarantee period between surgery and randomisation, although adhering to a defined surgical procedure as has traditionally occurred for treatment trials may be a factor influencing outcome.
Should such information about the benefits of trials be included in the information given to patients? There is a need to avoid unduly influencing patients by selling only the positive aspects, and it has been suggested that it is unwise to wait until patients are offered a trial before outlining the issues involved (Baum, 1993) . Simes et al. (1986) compared two policies of obtaining consent: total disclosure of all information or an individual approach tailored for each patient. The study reported that patients in the total disclosure group were less willing to participate in clinical trials according to the response to a questionnaire, although the difference in actual refusal rates was not significant. What was not reported was whether there was any difference in the time taken to apply either policy. Since lack of time was the major deterrent to participation identified in a recent survey of clinicians participating in cancer clinical trials, an information strategy which laid the ground work for a trial may be of benefit.
The issue of informed consent (or informed dissent) continues to be thorny and will remain of considerable concern to both patients and public alike for some considerable time. It is too big an issue to be tackled sensibly here.
A recent publication from the Department of Health, Assessing the Effects of Health Technologies (Advisory Group for Health Technology Assessment, 1992) , emphasises the importance of clinical trials in identifying which new treatments are an improvement over conventional ones, and states that, when the optimal treatment is unk-nown, patients should be treated within trials. It lacks, however, any comment on how to increase patient recruitment into trials. At present there is a disincentive for doctors to enter patients into clinical trials because of the extra work involved for very little associated benefit. Consideration must be given to providing incentives to encourage doctors to undertake this extra work. The purchaser-provider arrangements may not include an element for research, and this may be a major determinant of whether a doctor is able to take part in research. What should be included in any consideration of the costs of clinical research are the costs associated with the uncontrolled use of therapies that have not been evaluated. A relatively straightforward way to ease some of the burden associated with clinical trials would be the introduction of a central committee to review the ethics of proposed research; one application to a central committee would be easier than the multiple applications currently required. At the very least, the introduction of a single form which could be used nationally for submissions to local research ethics committees would represent considerable progress in facilitating trials.
Within the health care system only limited resources are available, and the extra financial costs that conducting clinical trials imposes above the costs of providing 'best standard care' have to be considered. In practice, the financial burden of trials may be less than generally assumed since many of the investigations associated with them should form part of good clinical practice. Clearly data collection and management require extra resources, but these can readily be identified as research costs. It is timely for an analysis of the extra costs of clinical trials to be carried out and for the source of funding to cover these to be identified, so that clinical trials do not deplete resources for routine patient care. We welcome the recommendation of the Culyer Committee that this should be done (Culyer, 1994) .
This study suggests that the majority of patients are either enthusiastic about entering clinical trials or uncertain. Only a small minority are unwilling to participate. A publicity campaign to inform patients of the potential advantages of participating in clinical trials, which also addresses their anxieties, may have the effect of providing consumer pressure on doctors to be more active in clinical research.
